文献速递消化道肿瘤放疗

二甲双胍联合同期放化疗提高直肠癌病理缓解的I/II期试点试验

Metformin with neoadjuvant chemoradiation to improve pathologic response in rectal cancer: A pilot phase I/II trial.
PubMed 文献 · Clin Transl Radiat Oncol · 2021-07-22

该单中心试点研究纳入16例非糖尿病直肠癌患者,在长程新辅助放化疗(50.4 Gy/28次联合卡培他滨)期间及前后口服二甲双胍,仅观察到1-2级不良事件;3例临床完全缓解未手术,12例手术者中2例病理完全缓解,pCR/cCR合计33%(95%CI 19-47%),需85例才能获得误差10%的95%CI。

要点

  • 二甲双胍联合同期放化疗未增加毒性,仅见1-2级不良事件。
  • pCR/cCR合计33%(95%CI 19-47%),16例中3例cCR、2例pCR。
  • 结果为未来II期试验设计提供样本量依据,需85例。

核心结论

  • 二甲双胍加入直肠癌新辅助放化疗未明显增加毒性,pCR/cCR率为33%(95%CI 19-47%),需进一步II期试验验证。

研究设计与样本

  • 单中心试点I/II期试验,纳入16例活检确诊、拟行长程新辅助放化疗的非糖尿病直肠癌患者。
  • 放疗50.4 Gy分28次,同期每日卡培他滨825 mg/m2每日两次。
  • 二甲双胍500 mg每日两次,于放化疗前2周、期间及结束后4周自行服用。

主要发现

  • 16例入组,1例退出;仅观察到1级或2级不良事件。
  • 3例达临床完全缓解(cCR)未手术;12例手术者中2例达病理完全缓解(pCR)。
  • pCR/cCR合计33%(95%CI 19-47%),需85例才能获得误差10%的95%CI。

关键数值与推荐

  • pCR/cCR率33%(95%CI 19-47%),基于16例入组患者。
  • 放疗剂量50.4 Gy/28次,卡培他滨825 mg/m2每日两次,二甲双胍500 mg每日两次。

临床怎么用

  • 该方案毒性可控,可作为非糖尿病直肠癌新辅助放化疗联合二甲双胍的参考。
  • pCR/cCR数据尚不足以改变临床实践,需等待II期试验结果。

局限性

  • 单中心试点研究,样本量仅16例,1例退出。
  • 主要目的是构建pCR率置信区间以估算II期样本量,非疗效确证。
  • 未设对照组,无法直接比较加用二甲双胍的疗效差异。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Neoadjuvant radiotherapy with or without chemotherapy decreases the risk of local recurrence after surgery for rectal cancer. Emerging data suggest that diabetic patients on metformin may have improved cancer outcome after radiotherapy. A single institutional pilot study was performed to determine if metformin given concurrently with long course chemoradiation (CRT) may improve pathologic complete response (pCR) in non-diabetic rectal cancer patients. The study was designed to construct a confidence interval (CI) for the pCR rate to determine the sample size for a phase 2 trial. METHODS: Non-diabetic patients with biopsy confirmed rectal cancer deemed candidates for long course neoadjuvant CRT were invited to participate. Radiation consisted of 50.4 Gy in 28 daily fractions with concurrent daily capecitabine (825 mg/m2 twice daily). Participants self-administered metformin (500 mg of twice daily) 2 weeks prior to, during and for 4 weeks after CRT. RESULTS: A total of 16 patients were accrued. One patient withdrew from the study. Only grade 1 or 2 adverse events were observed. Three patients had a clinical complete response (cCR) and did not undergo surgery. Of the 12 patients who underwent surgery, there were two pCRs. For the combined pCR/cCR rate of 33% (95% CI 19-47%), a total of 85 patients will be required to yield a 95% CI with a 10% margin of error. CONCLUSIONS: Adding metformin to neoadjuvant CRT for rectal cancer does not appear to enhance toxicities. These results will be used to refine the design and conduct of a future phase 2 trial to determine whether adding metformin to CRT improves pCR/cCR rates.

来源:Clin Transl Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Wong CS, Chu W, Ashamalla S, et al. Metformin with neoadjuvant chemoradiation to improve pathologic response in rectal cancer: A pilot phase I/II trial. Clin Transl Radiat Oncol. 2021. PMID: 34401534. doi:10.1016/j.ctro.2021.07.001

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。